Fibrinolysis is the system primarily responsible for removal of fibrin deposits and blood clots
in the vasculature. The terminal enzyme in the pathway, plasmin, is formed from its …

All trans-retinoic acid (atRA) has potent anti-inflammatory and antiplatelet activity, but its
clinical translation as an antithrombotic drug has been hampered by its low therapeutic …

Cell‐based nanotherapy holds great potential to transform diagnosis and treatment patterns
for human diseases, especially for cardiovascular diseases (CVDs). Surface coating with …

Background Intravenous administration of fibrinolytic drugs, such as recombinant tissue
plasminogen activator (rtPA) is the standard treatment of acute thrombotic diseases …

In this work, we fabricated rutin (RTN)-loaded albumin nanoparticles (RTN-ALB-NPs) and
abciximab (ABX) coated RTN-loaded albumin nanoparticles (ABX-RTN-ALB-NPs) for the …

Liposomes have been extensively explored as drug carriers, but their clinical translation has
been hampered by their low drug-loading content and premature leakage of drug payloads …

Thrombolytic therapy is one of the most effective treatments for thrombus dissolution and
recanalization of blocked vessels in thrombotic diseases. However, the application of the …

Thrombotic blockages within blood vessels give rise to critical cardiovascular disorders,
including ischemic stroke, venous thromboembolism, and myocardial infarction. The current …

Thrombus-induced cardiovascular diseases threaten human health. Current treatment
strategies often rely on urokinase plasminogen activator (uPA) for its efficacy, yet it has such …

Thrombus has long been the major contributor of death and disability because it can cause
adverse effects to varying degrees on the body, resulting in vascular blockage, embolism …